Published in

Springer, Magazine of European Medical Oncology, 1(13), p. 27-31, 2020

DOI: 10.1007/s12254-020-00582-4

Links

Tools

Export citation

Search in Google Scholar

Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network

Journal article published in 2020 by Hildegard T. Greinix, Andishe Attarbaschi, Michael Girschikofsky, Richard Greil, Wolfgang Holter, Peter Neumeister, Christina Peters, Andreas Petzer, Jakob Rudzki, Peter Schlenke, Clemens A. Schmitt, Wolfgang Schwinger, Dominik Wolf, Nina Worel ORCID, Ulrich Jaeger
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

SummaryChimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasting B cell aplasia. Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers.